Free Trial

Alpha Cognition (ACOG) to Release Earnings on Monday

Alpha Cognition logo with Medical background

Key Points

  • Alpha Cognition is set to release its Q2 2025 earnings on August 11th, with analysts expecting a loss of ($0.84) per share and revenue of $2.32 million.
  • The company's previous earnings report showed a better-than-expected EPS of ($0.20), exceeding estimates by $0.38 and revenue of $2.93 million.
  • HC Wainwright has reaffirmed a "buy" rating for Alpha Cognition, setting a price target of $20.00 on its shares.
  • MarketBeat previews top five stocks to own in September.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Alpha Cognition to post earnings of ($0.84) per share and revenue of $2.32 million for the quarter.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.38. The business had revenue of $2.93 million for the quarter, compared to the consensus estimate of $0.50 million.

Alpha Cognition Stock Performance

NASDAQ ACOG opened at $9.15 on Monday. The business has a 50 day simple moving average of $9.69 and a 200 day simple moving average of $7.21. Alpha Cognition has a 52-week low of $3.75 and a 52-week high of $11.54. The stock has a market cap of $146.58 million, a price-to-earnings ratio of -7.62 and a beta of 2.72.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Alpha Cognition in a research note on Friday, May 16th.

Get Our Latest Research Report on Alpha Cognition

About Alpha Cognition

(Get Free Report)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alpha Cognition Right Now?

Before you consider Alpha Cognition, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.

While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines